Cure51

About Cure51

Cure51 is a tech-bio company focused on deciphering the secrets of long-term cancer survivors (patients living more than 5 years after diagnosis with highly lethal cancers) to eradicate cancer by 2035. They aim to create a world where cancer outliers become the blueprint for curing everyone, building a unique clinical and multi-omics database by focusing on exceptional survivors across all continents.

Products & Services

Cancer Survivor Data Analysis:Collecting unique data from thousands of long-term cancer survivors to build a clinical and multi-omics database for cancer eradication.

Precision Medicine Tools:Developing tools to deliver actionable insights for discovering novel therapeutics in oncology.

Oncology Drug Programs:Designing best-in-class drugs by discovering multimodal signatures and creating a library of robust targets through collaboration with scientific partners.

Specialties

Computational Biology Oncology Research Precision Medicine Cancer Survivor Data Analysis Drug Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 16406335 MR: - FA: €15 million FAN: 16406335	D: 2024-03-20 FD: 2024-03-20	5 investors

Seed Latest

2024-03-20

$16.4M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Camille

J

Jean-Luc

Exceptional Cancer Survivor

Y

Yann

S

Samantha

M

Maria

C

Catherine

View 13 more team members with Pro

Unlock Full Team Directory

Recent News

Cure51 Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised